Literature DB >> 23205291

Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one?

Giulio Metro1, Vincenzo Minotti, Lucio Crinò.   

Abstract

Entities:  

Year:  2012        PMID： 23205291      PMCID： PMC3506794          DOI： 10.3978/j.issn.2072-1439.2012.10.06

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  18 in total

1.  Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.

Authors:  Egbert F Smit; Anne-Marie C Dingemans; Frederik B Thunnissen; Monique M Hochstenbach; Robert-Jan van Suylen; Pieter E Postmus
Journal:  J Thorac Oncol       Date:  2010-05       Impact factor: 15.609

2.  Abstracts of the AACR (American Association for Cancer Research)-IASLC (International Association for the Study of Lung Cancer) Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine. January 8-11, 2012. San Diego, California, USA.

Authors: 
Journal:  Clin Cancer Res       Date:  2012-02-01       Impact factor: 12.531

3.  Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

Authors:  Giorgio Scagliotti; Silvia Novello; Joachim von Pawel; Martin Reck; José Rodrigues Pereira; Michael Thomas; José Elias Abrão Miziara; Beatrix Balint; Filippo De Marinis; Alan Keller; Osvaldo Arén; Maria Csollak; Istvan Albert; Carlos Henrique Barrios; Francesco Grossi; Maciej Krzakowski; Lisa Cupit; Frank Cihon; Sandra Dimatteo; Nasser Hanna
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

4.  A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.

Authors:  Joline S W Lind; Anne-Marie C Dingemans; Harry J M Groen; Frederik B Thunnissen; Otto Bekers; Daniëlle A M Heideman; Richard J Honeywell; Elisa Giovannetti; Godefridus J Peters; Pieter E Postmus; Robert Jan van Suylen; Egbert F Smit
Journal:  Clin Cancer Res       Date:  2010-04-15       Impact factor: 12.531

5.  Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.

Authors:  Ronan J Kelly; Arun Rajan; Jeremy Force; Ariel Lopez-Chavez; Corrine Keen; Liang Cao; Yunkai Yu; Peter Choyke; Baris Turkbey; Mark Raffeld; Liqiang Xi; Seth M Steinberg; John J Wright; Shivaani Kummar; Martin Gutierrez; Giuseppe Giaccone
Journal:  Clin Cancer Res       Date:  2011-01-11       Impact factor: 12.531

Review 6.  Advances on EGFR mutation for lung cancer.

Authors:  Giulio Metro; Lucio Crinò
Journal:  Transl Lung Cancer Res       Date:  2012-03

7.  A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.

Authors:  Heather A Wakelee; Ju-Whei Lee; Nasser H Hanna; Anne M Traynor; David P Carbone; Joan H Schiller
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

8.  Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.

Authors:  George R Blumenschein; Ulrich Gatzemeier; Frank Fossella; David J Stewart; Lisa Cupit; Frank Cihon; James O'Leary; Martin Reck
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544

9.  The BATTLE trial: personalizing therapy for lung cancer.

Authors:  Edward S Kim; Roy S Herbst; Ignacio I Wistuba; J Jack Lee; George R Blumenschein; Anne Tsao; David J Stewart; Marshall E Hicks; Jeremy Erasmus; Sanjay Gupta; Christine M Alden; Suyu Liu; Ximing Tang; Fadlo R Khuri; Hai T Tran; Bruce E Johnson; John V Heymach; Li Mao; Frank Fossella; Merrill S Kies; Vassiliki Papadimitrakopoulou; Suzanne E Davis; Scott M Lippman; Waun K Hong
Journal:  Cancer Discov       Date:  2011-06-01       Impact factor: 39.397

10.  Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Bonne Biesma; David Heigener; Joachim von Pawel; Timothy Eisen; Jaafar Bennouna; Li Zhang; Meilin Liao; Yan Sun; Steven Gans; Kostas Syrigos; Etienne Le Marie; Maya Gottfried; Johan Vansteenkiste; Vincente Alberola; Uwe Phillip Strauss; Elaine Montegriffo; Teng Jin Ong; Armando Santoro
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544
View more
  1 in total

Review 1.  Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer.

Authors:  James E Frampton
Journal:  Drugs       Date:  2013-12       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.